Remarkable market opportunities exist for developers of infectious disease-related technologies, but developers need to be aware of the intricacies of patenting, say Helene Carlson and Elizabeth Haanes.
Remarkable market opportunities exist for innovative developers of infectious disease-related technologies, but such developers need to be aware of the intricacies of patenting technologies in this field, say Helene Carlson and Elizabeth Haanes.
The global rise of resistant infectious agents and the threat of pandemics and bio-warfare create an enormous need in fields such as infectious disease (ID) therapeutics, vaccines and personalised medicine. In addition, global initiatives are providing incentives for commercial entities to develop new diagnostics and improved versions of existing therapeutics and vaccines. The current climate requires ID innovators to take a strategic view of the intellectual property issues surrounding proposed products as well as products in development. A proactive intellectual property strategy over the full life cycle will maximise revenue (mining for gold) and reduce risks such as litigation (avoiding land mines).
Avoiding land mines
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Infections disease-related technology, strategic patent considerations